Table 1.
Characteristics of included randomized trials.
|
Study |
Cancer types |
Sample size --30480762-304807620 |
Mean age, years (SD or range) 520707620 |
Gender (Male/Female)--24130762-241307620 |
BMI--43180762-431807620 |
Treatment protocol--33655762-336557620 |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Exp | Con | Exp | Con | Exp | Con | Exp | Con | Exp | Con | ||
| Kiek S |
GC | 30 | 30 | NA | NA | NA | NA | NA | NA | Standard PN + ω-3 PUFA after operation; (1-9d); |
Standard PN 9 days after operation;(1-9d); |
| Liang B | CRC | 20 | 21 | 55.80 ± 10.10 | 59.19 ± 10.61 | 10/10 | 15/6 | 23.38 ± 2.38 | 23.92 ± 2.84 | SO + FO after operation; (1-7d); | SO after operation; (1-7d) |
| Zhang C H | GIC | 32 | 32 | 56.6 ± 11.9 | 56.8 ± 12.6 | 20/12 | 24/8 | 23.1 ± 2.4 | 23.5 ± 2.6 | Lipoplus(MCT + LCT + ω-3 PUFA) after operation; (1-5d); | Lipofund (MCT + LCT) after operation; (1-5d); |
| Zhu M W |
CRC | 29 | 28 | 69.8 ± 10.5 | 70.8 ± 6.4 | 17/11 | 16/13 | 22.9 ± 3.1 | 23.2 ± 3.6 | 1.2 g/kg SO per day after operation; (1-7d); | 0.2 g/kg FO and 1.0 g/kg SO per day after operation; (1-7d); |
| Sorensen L S | CRC | 74 | 74 | 64 ± 11 | 71 ± 10 | 44/30 | 36/38 | 26 ± 5 | 26 ± 5 | ω-3PUFA enriched(ONS) (Supportan, 200 ml twice daily) providing 2 g EPA and 1 g DHA; (7 days before and 7 days after operation); |
Standard isocaloric and isonitrogenous ONS; (7 days before and 7 days after operation); |
| Zhang Y | GIC | 32 | 32 | 58.13 ± 11.32 | 56.40 ± 11.57 | 17/15 | 16/16 | 22.26 ± 2.27 | 23.88 ± 2.63 | LCT:MCT = 5:5 after operation; (1-5d); | LCT:MCT:ω-3PUFA = 5:4:1 after operation; (1-5d); |
| Wei Z | GC | 26 | 25 | 50.5(29–75) | 59(36–74) | 15/11 | 11/9 | 22.2(15.–28.1) | 22.5(17–29.7) | The fat emulsion used was omega-6 lipid (20% Intralipid) after operation; (≧6d); |
The omega-6 lipid content of TPN was partially replaced by ω-3PUFA(10%Omegave) up to 0.2 g/kg body weight daily after surgery; (≧6d); |
| Ma C J | GIC | 44 | 41 | 61.55 ± 9.78 | 62.85 ± 10.12 | 29/22 | 27/21 | 23.45 ± 3.44 | 23.91 ± 3.79 | ω-3PUFA enriched intravenous fat emulsion (IVFE) after operation; (1-7d); | lipid emulsion comprised of soybean oil and MCTs after operation; (1-7d); |
| Nathalie B | CRC | 18 | 23 | 65 (64–75) | 69 (63–74) | 13/5 | 15/8 | 26.9(25.1–27.8) | 25.7(23.5–29.4) | 2 intravenous ω-3PUFA infusions the night before and the morning after operation; |
2 intravenous saline control infusions the night before and the morning after operation; |
| Liu Y M | GC | 25 | 27 | 54.6 ± 10.3 | 56.1 ± 9.8 | 18/7 | 19/8 | NA | NA | Enteral nutrition preparations twice a day after operation, 500 ml each time, including 1.5 g ω-3PUFA;(1–3 months) | Routine enteral nutrition after surgery; (1–3 months) |
BMI,body mass index;CRC, colorectal cancer; GC, gastric cancer; GIC, gastrointestinal cancer; PUFA,polyunsaturated fatty acids;SO,soybean oil;FO, fish oil;DHA,docosahexaenoic acid;EPA,eicosapentaenoic acid; LCT,long-chain triglycerides;MCT,mediumchain triglycerides, Exp, experimental;Con, control; NA, no available.